Zolinza (vorinostat) / Merck (MSD) - LARVOL DELTA

Spared corticospinal neurons activate an endogenous plasticity program after partial CNS injury. (PubMed, bioRxiv) - "Network and drug perturbation analyses identified ARHGEF12 suppression and vorinostat treatment as complementary target- and state-based strategies to enhance neurite regeneration in human neurons. Together, these findings define key components of endogenous plasticity and provide a framework for discovering therapeutic targets for neural repair."

Journal • CNS Disorders • Orthopedics

Vorinostat for graft-versus-host disease prevention in pediatric and young adult patients with hematologic malignancies. (PubMed, JCI Insight) - P1/2 | "These findings support randomized evaluation of vorinostat-based GVHD prophylaxis in pediatric and AYA HCT."

Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics • Transplantation

VALOR study: A phase II trial of vorinostat to augment response to 177Lutetium-PSMA-617 in the treatment of patients with PSMA-low metastatic castration resistant prostate cancer. (ASCO 2025) - P2 | "Funded by Novartis Clinical Trial Registration Number: NCT06145633 Background: 177Lu-PSMA-617 (LuPSMA), a prostate specific membrane antigen (PSMA) targeting radioligand therapy, is approved for men with mCRPC. These molecular studies will be correlated with the pre/post vorinostat PSMA PET images and clinical outcomes with LuPSMA. Clinical trial information: NCT06145633."

Clinical • Metastases • P2 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CTCs • FOLH1

HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity. (PubMed, Nat Commun) - "In vivo, suberoylanilide hydroxamic acid mitigates doxorubicin-induced cardiotoxicity. These findings identify histone deacetylase inhibition as a cardioprotective repurposing strategy and reveal a mechanistic link between epigenetic regulation and anthracycline-associated cardiotoxicity."

Journal • Cardiovascular • Oncology • HDAC4 • MYH7

A novel CAVIN1/GAS5 axis suppresses skin fibrosis through mitochondrial fission-mediated attenuation of the TGF-β/Smad pathway. (PubMed, Burns Trauma) - "Functional validation was performed by using primary keloid fibroblasts (KFs) with gain- and loss-of-function approaches, RNA immunoprecipitation sequencing (RIP-seq), and actinomycin D chase assays. Our study reports a novel CAVIN1/GAS5 axis that concurrently targets mitochondrial fission and the TGF-β/Smad pathway to suppress skin fibrosis. These findings not only reveal a previously unrecognized mechanistic link in keloid pathogenesis but also identify CAVIN1 as a promising therapeutic target, with vorinostat as a potential repurposable drug for treating fibrotic skin disorders."

Journal • Dermatology • Fibrosis • Immunology • GAS5 • TGFB1

Pharmacological inhibition of HDAC1-mediated histone delactylation at the Gria1 promoter promotes SPP1 expression and microglial M2 polarization to alleviate traumatic brain injury. (PubMed, Mol Immunol) - "Pharmacological inhibition of HDAC1, particularly with suberoylanilide hydroxamic acid (SAHA), or lactate supplementation restored histone lactylation and promoted M2 polarization...In a mouse TBI model, SAHA improved neurological recovery, reduced cortical lesions, upregulated Gria1 and SPP1, increased CD206, decreased CD86, and attenuated microglial activation. Collectively, pharmacological inhibition of HDAC1-mediated histone delactylation at the Gria1 promoter enhances Gria1-dependent SPP1 expression, thereby promoting microglial M2 polarization and attenuating neuroinflammation after TBI."

Journal • CNS Disorders • Inflammation • Vascular Neurology • CD86 • GRIA1 • HDAC1 • MRC1 • SPP1

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL) (ASH 2022) - "In the Phase III MAVORIC trial comparing mogamulizumab to vorinostat, mogamulizumab-associated rash (MAR) was reported in 25% of patients (pts) and was more common in responders than in non-responders. The development of MAR in patients with CTCL is associated with higher rates of CR and ORR and significantly longer PFS and OS. CR/PR response in blood were associated with improved PFS. Additionally, 40% of patients who developed MAR and discontinued mogamulizumab had ongoing responses without additional systemic therapy."

IO biomarker • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • CCR4

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial (ASH 2022) - "Later, meta-analysis suggested the link to be secondary to len in combination with melphalan...Methods Myeloma XI was a phase III, randomised, multi-centre, parallel group design, open-label trial comparing cyclophosphamide, thalidomide, len, carfilzomib and bortezomib induction combinations and len as maintenance treatment in newly diagnosed patients...Patients in both pathways were randomised to maintenance with len (+/- vorinostat) or active observation...However, deaths due to myeloma were lower in patients treated with len. We suggest that clinic review of patients receiving maintenance len should include a history focused on identifying possible SPM, so intervention can be made early."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Genetic Disorders • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Leukemia • Melanoma • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • Prostate Cancer • Skin Cancer • Solid Tumor • Transplantation

Comparative efficacy of therapeutic strategies for recurrent or refractory glioblastoma: a systematic review and network meta-analysis. (PubMed, Front Neurol) - "Compared with lomustine, bevacizumab plus lomustine significantly improved PFS (HR = 0.57, 95% CI: 0.40-0.80), and remained significant after excluding small trials (HR = 0.58, 95% CI: 0.34-0.97). Bevacizumab plus vorinostat had the highest numerical P-score for PFS, although its effect was not statistically significant...No treatment significantly improved ORR versus bevacizumab, whereas nivolumab was associated with lower odds of response (OR = 0.28, 95% CI: 0.14-0.57). Excluding small trials had limited influence on PFS and OS findings but altered the ORR ranking by removing the highly ranked ERC1671-based regimen...No treatment showed a confirmed OS advantage, and the favorable numerical signal for rindopepimut plus bevacizumab should not be generalized beyond EGFRvIII-positive patients. P-score rankings should be considered exploratory and interpreted alongside effect estimates, confidence intervals, sample sizes, molecular eligibility, safety, and treatment burden...."

Clinical • Journal • Retrospective data • Review • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Single Cell RNA-sequencing Reveals IGFBP3+Cafs as a Critical Player in Lung Cancer Metastasis (IASLC-WCLC 2026) - "The expression of IGFBP3 was regulated epigenetically and positively associated with IGF2. Together, targeting IGFBP3 + CAFs may be a promising approach of inhibiting NSCLC metastasis."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CAFs • CD31 • IGF2 • IGFBP3 • PECAM1 • PTPRC

Laryngeal NUT Carcinoma With BRD4::NUTM1 Fusion: A 4-Year Clinical Course Highlighting the Limitations of Current Multimodal Therapy. (PubMed, Cancer Rep (Hoboken)) - "Early molecular diagnosis and biologically informed multimodal strategies are essential for managing laryngeal NUT carcinoma and overcoming treatment resistance."

IO biomarker • Journal • Gene Therapies • Infectious Disease • Laryngeal Cancer • NUT Midline Carcinoma • Oncology • Squamous Cell Carcinoma • Testicular Cancer • BRD4 • NUTM1

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results. (ASCO 2023) - P1/2 | "To our knowledge, this is the first randomized trial investigating the combination of HDAC inhibition and anti-PD1 therapy in NSCLC. Although the combination arm had a numerically higher ORR compared to P monotherapy, the result did not meet the primary endpoint for significance. While there were no new safety signals with the combination therapy, reduction or interruption in V dose occurred frequently, which may have contributed to lack of survival differences between arms."

Clinical • IO biomarker • Metastases • P2 data • Cardiovascular • Fatigue • Hepatology • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pneumonia • Solid Tumor • IFNG

Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial (ESMO 2023) - P2 | "Conclusions PEVOsq study met its primary endpoint, documenting promising anti-tumoral activity of the association of P+V in heavily pretreated SCAC pts. However, the high rate of toxicities requires a special attention in future trials."

Clinical • Metastases • P2 data • Pan tumor • Anal Carcinoma • Gastrointestinal Cancer • Oncology • Squamous Cell Carcinoma • PD-L1

Research Progress of Histone Deacetylase and Its Inhibitors in Endometriosis. (PubMed, Reprod Sci) - "It also summarizes the therapeutic potential of histone deacetylase inhibitors (HDACis) such as Vorinostat, Romidepsin, and Butyrate demonstrated in preclinical studies, and analyzes the main challenges currently faced in clinical translation. Finally, this article discusses the challenges and future research directions for developing novel endometriosis therapies targeting HDACs, aiming to provide references for in-depth research and clinical translation in this field."

Journal • Review • Endometriosis • Gynecology • Inflammation • Women's Health

Phase I Study of 131I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. (PubMed, J Clin Oncol) - "MIBG combined with dinutuximab was well tolerated with encouraging antitumor activity. Vorinostat added to this combination may augment responses in this heavily pretreated patient population."

Journal • P1 data • Fatigue • Neuroblastoma • Oncology • Pneumonia • Solid Tumor

Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade. (PubMed, Blood) - P1 | "Pembrolizumab and vorinostat was well-tolerated with a high ORR rate in RR cHL including in anti-PD1-refractory disease."

Journal • Cardiovascular • Diffuse Large B Cell Lymphoma • Endocrine Disorders • Follicular Lymphoma • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Hypertension • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Renal Disease • Thrombocytopenia • Transplantation

Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population (clinicaltrials.gov) - P2 | N=55 | Recruiting | Sponsor: Sung Won Choi | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2028 ➔ Sep 2028 | Trial primary completion date: Jun 2028 ➔ Sep 2028

Enrollment open • Trial completion date • Trial primary completion date • Graft versus Host Disease • Immunology • Transplantation

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial. (PubMed, Br J Haematol) - "Combination lenalidomide-vorinostat appeared to be poorly tolerated with more dose modifications, fewer cycles of maintenance therapy delivered and higher rates of discontinuation due to toxicity than lenalidomide alone. The trial did not meet its primary end-point, there was no benefit from the addition of vorinostat to lenalidomide maintenance."

Journal • P3 data • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Two-Year Outcomes of Molecularly Tailored RCHOP-X in Newly Diagnosed Diffuse Large B-Cell Lymphoma (SOHO 2026) - "Objective: To evaluate the feasibility, efficacy, and safety of molecularly adapted rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP-X) versus standard R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL), testing the hypothesis that genotype-directed therapy improves outcomes in high-risk patients...Interventions: One initial RCHOP cycle (bridge therapy), followed by five R-CHOP-X cycles with subtype-specific add-ons (vorinostat, acalabrutinib, decitabine, or lenalidomide) based on LymphGen classification via targeted sequencing (19-gene panel, n = 35; 60-gene panel, n = 34)... Molecularly adapted R-CHOP-X is feasible and associated with superior response rates and 2-year survival compared with historical R-CHOP in high-risk DLBCL. Expanded panels improve subtyping. Multicenter randomized trials are required before routine clinical adoption."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Randomized Treatments for Myelodysplastic Syndrome and Related Disorders: A Comprehensive Component Network Meta-Analysis of Randomized Controlled Trials (SOHO 2026) - "Compared with best supportive care, higher odds of complete remission were observed for azacitidine, azacitidine plus lenalidomide, azacitidine plus vorinostat, panobinostat plus azacitidine, APR-246 plus azacitidine, decitabine, decitabine plus valproic acid, and glasdegib plus cytarabine. This review combines broad trial identification, structured screening, detailed extraction, and treatment level synthesis across a complex therapeutic landscape. Its findings may support future guidelines, whereas the contrast between regimen- and component-level effects leaves key clinical questions for the full review to resolve."

Retrospective data • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

Identification of TIPARP, BCL6 and PLIN2 as Potential Ferroptosisrelated Biomarkers for Osteoarthritis. (PubMed, Curr Med Chem) - "In conclusion, our study identified TIPARP, BCL6, and PLIN2 as potential key FRGs in OA, providing novel insights for understanding the pathogenesis of OA."

Biomarker • Journal • Immunology • Osteoarthritis • Pain • Rheumatology • BCL6 • PARP1 • PLIN2 • TIPARP

Cefuroxime combined with metronidazole alleviates sepsis-induced cognitive dysfunction. (PubMed, Neuroscience) - "Furthermore, administration of HDAC2 inhibitor vorinostat (SAHA) similarly attenuated sepsis-associated cognitive dysfunction. Additionally, the treatment normalized the dysregulated expression of TrkB, PD-1, and PD-L1, which are critical regulators of synaptic plasticity and immune responses. Collectively, this study highlights the therapeutic potential of targeting inflammation and synaptic integrity in SAE and provides a rationale for further exploring the role of antibiotics in cognitive recovery among sepsis survivors."

IO biomarker • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Infectious Disease • Inflammation • Septic Shock • HDAC2 • NTRK2 • PD-1 • SYP

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. (clinicaltrials.gov) - P1 | N=52 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jul 2026 ➔ Jun 2027

Trial completion date • B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Rational design of soft liposomal drug carriers: Computational Insights into how lipid acyl chain Identity, and hydrophobic drug loading drive liposomal deformability | Poster Board #D16 (ACS-Fall 2026) - "We first looked at how three hydrophobic anticancer drugs, Panobinostat, Ki16425, and Vorinostat, changed the mechanics of DOPC bilayers. The softest mixtures had KA values that were 23% to 30% lower than those of pure DOPC. The stiffness hierarchy among PC lipids (DOPC > SOPC ≥ POPC) is the inverse of the chain order hierarchy (SOPC > POPC > DOPC), showing a disconnect between KA and SC."

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab (clinicaltrials.gov) - P2 | N=118 | Not yet recruiting | Sponsor: New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Jul 2031 ➔ Dec 2031 | Initiation date: Jul 2026 ➔ Dec 2026 | Trial primary completion date: Jul 2030 ➔ Dec 2030

Trial completion date • Trial initiation date • Trial primary completion date • Neuroblastoma • Oncology • Solid Tumor